Progyny (PGNY) Q1 2026 earnings review
Core Growth Obscured by Client Loss, While Investments Squeeze EBITDA
Progyny's Q1 2026 optics are messy but fundamentally sound. A reported 1.4% YoY revenue growth hides a healthy 12.2% core expansion when stripping out the large client lost last year. The real story, however, is on the margin line. Despite gross margins expanding a massive 190 basis points to 25.3%, Adjusted EBITDA actually declined 2.1% YoY to $56.6M. The company is plowing its gross profit gains straight back into platform and member experience investments. To support the stock through this noisy transition period, management aggressively exhausted its $200M share repurchase program, buying 5.5 million shares in Q1 alone. Guidance points to sequential acceleration, but investors must decide if the heavy OPEX investments will deliver the promised scale.
🐂 Bull Case
Excluding the departed large client, Q1 revenue grew 12.2%. The transition noise will be completely flushed out by H2 2026, allowing the true growth rate to shine through.
Management is taking advantage of the stock's valuation, exhausting the $200M buyback program and signaling the Board will likely authorize another program by May. This provides a hard floor for EPS.
🐻 Bear Case
Gross margins are up, but OPEX is up more. A 2.1% YoY absolute decline in Adjusted EBITDA (and a margin drop from 17.8% to 17.2%) proves that scaling the platform is becoming more expensive.
Total ART cycles fell 3% YoY to 15,647. Even factoring in the lost client, the lack of absolute volume growth puts intense pressure on pricing and ancillary services to carry the top line.
⚖️ Verdict: ⚪
Neutral. The core business is surviving the loss of its mega-client relatively unscathed. However, the step-back in Adjusted EBITDA margins due to ongoing investments prevents this from being a clean beat-and-raise.
Key Themes
Underlying Demand Survives the Client Transition
The optical 1.4% revenue growth is entirely an artifact of a single large client departing in mid-2025. Excluding the $31.3M this client contributed in 25Q1, core revenue expanded by 12.2%. This proves the company's 'land and expand' model is functioning, with average members actually increasing by 7% YoY to 7.18 million despite the headwind.
Margin Squeeze from Heavy Investments
A clear divergence has formed between gross and operating margins. Q1 gross margin expanded 190 basis points to 25.3% due to care management efficiencies. However, Adjusted EBITDA margin contracted from 17.8% to 17.2%, causing absolute EBITDA to drop 2.1% YoY to $56.6M. Management explicitly blamed 'planned investments to further enhance both our platform and the member experience.' Growth is currently requiring outsized OPEX.
Contradictory Narrative on Utilization
Management claimed 'member engagement trended to the higher end of our expectations,' reflecting robust demand. Yet, the hard data shows Assisted Reproductive Treatment (ART) cycles actually declined 3.1% YoY (from 16,160 to 15,647). While the lost transition client accounts for some of this, a drop in absolute treatment volumes contradicts the bullish narrative surrounding engagement and demand.
Demographic Tailwinds Solidify Base
CEO Pete Anevski cited newly released CDC data highlighting a massive structural shift: women over 30 now account for more than half of all U.S. births, representing their highest proportion ever. As society defers family building, natural conception becomes harder, structurally embedding Progyny's services as a necessity rather than a luxury perk for employers.
Aggressive EPS Support via Buybacks
The company effectively put a floor under its stock by spending $116.4M in Q1 alone to repurchase 5.5 million shares. This fully exhausted the $200M program initiated in November 2025 (8.8M total shares retired). This financial engineering helped drive a 70% YoY increase in GAAP Diluted EPS ($0.17 to $0.29) and shielded Adjusted EPS. A new program announcement is slated for May.
Broadening the Platform Beyond Core Fertility
While fertility remains the engine, Progyny's transition into a holistic women's health platform is well underway. The strategic focus on integrating solutions like pelvic floor therapy, menopause, and postpartum support serves a dual purpose: it increases upsell vectors with existing clients and justifies the current heavy OPEX investments in the platform interface.
Other KPIs
Accelerating. Rose 10% YoY. The 190 basis-point margin expansion to 25.3% reflects deep operational efficiencies in care delivery and favorable comparisons due to lower stock-based compensation inside COGS. The core delivery model is scaling beautifully, even if operating expenses are not.
Decelerating slightly compared to $49.8M in 25Q1. Management maintains a high conversion rate of Adjusted EBITDA to operating cash flow. The slight YoY drop is largely an artifact of the customary Q1 accounts receivable build as new client payment flows are established.
Guidance
Accelerating. The midpoint represents a 4.7% YoY growth rate on a reported basis, a clear acceleration from Q1's 1.4%. Excluding the large transition client's 25Q2 contribution, this implies core growth accelerating to between 8.3% and 12.4%.
Accelerating. Implies full-year growth of 5.9% to 9.0%. When stripping out the $48.5M from the large transition client in 2025, underlying full-year growth sits at a very healthy 10.1% to 13.3%, validating the successful 2026 selling season.
Stable. Up from roughly $216-$220M in 2025. However, this represents an expected full-year margin of ~17.2%, meaning the margin contraction seen in Q1 is not a one-off, but the new expected baseline for the year as the company digests its platform investments.
Key Questions
ROI on Margin-Squeezing Investments
Adjusted EBITDA margin declined 60 bps this quarter due to platform investments. At what point in FY26 or FY27 do we expect these investments to scale and return the company to operating leverage expansion?
ART Cycle Dynamics
Total ART cycles declined 3% YoY. Can you provide the ART cycle growth rate strictly for the cohort of clients that were active in both periods (excluding the large departed client) to prove underlying volume demand remains robust?
Share Repurchase Philosophy
Having exhausted $200M in just over a quarter, how is the Board evaluating the size and pace of the next potential authorization? Will you continue to front-load purchases, or transition to a programmatic approach?